S 526

BENEFIT Act of 2023

Congress: 118 (2023–2025, Ended)
Chamber: Senate
Policy Area: Health
Introduced: Feb 16, 2023
Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Feb 16, 2023)
Official Text: https://www.congress.gov/bill/118th-congress/senate-bill/526

Sponsor

Name: Sen. Wicker, Roger F. [R-MS]
Party: Republican • **State:** MS • **Chamber:** Senate

Cosponsors (5 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Klobuchar, Amy [D-MN]	D · MN		Feb 16, 2023
Sen. Collins, Susan M. [R-ME]	R · ME		Mar 8, 2023
Sen. Braun, Mike [R-IN]	R · IN		Mar 28, 2023
Sen. Scott, Rick [R-FL]	R · FL		Oct 17, 2023
Sen. Hagerty, Bill [R-TN]	R · TN		Apr 30, 2024

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Feb 16, 2023

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
118 HR 1092	Identical bill	**Feb 24, 2023:** Referred to the Subcommittee on Health.

Summary (as of Feb 16, 2023)

Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2023 or the BENEFIT Act of 2023

This bill requires the Food and Drug Administration (FDA) to consider relevant patient experience data in the risk-benefit assessment framework used in the process for approving new drugs.

After a new drug application has been approved, the FDA's public statement about how it used patient experience data shall include a description of how such data was considered in the risk-benefit assessment framework.

Actions Timeline

- **Feb 16, 2023:** Introduced in Senate
- **Feb 16, 2023:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.